Development of novel therapy of schizophrenia in children and adolescents

Bibliography

• McClellan J, Stock S. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2013;52:976-90
   PubMed Web of Science ®Google Scholar
• Carlisle LL, McClellan J. Psychopharmacology of schizophrenia in children and adolescents. Pediatr Clin North Am 2011;58:205-18
   PubMed Web of Science ®Google Scholar
• Hollis C. Child and adolescent (juvenile onset) schizophrenia. A case control study of premorbid developmental impairments. Br J Psychiatry 1995;166:489-95
   PubMed Web of Science ®Google Scholar
• Hollis C. Developmental precursors of child- and adolescent-onset schizophrenia and affective psychoses: diagnostic specificity and continuity with symptom dimensions. Br J Psychiatry 2003;182:37-44
   PubMed Web of Science ®Google Scholar
• Kendall T, Hollis C, Stafford M, Taylor C. Recognition and management of psychosis and schizophrenia in children and young people: summary of NICE guidance. BMJ 2013;346:f150
   Google Scholar
• Rabinowitz J, Levine SZ, Hafner H. A population based elaboration of the role of age of onset on the course of schizophrenia. Schizophr Res 2006;88:96-101
   PubMed Web of Science ®Google Scholar
• Clemmensen L, Vernal DL, Steinhausen HC. A systematic review of the long-term outcome of early onset schizophrenia. BMC Psychiatry 2012;12:150-65
   PubMed Web of Science ®Google Scholar
• Amminger GP, Henry LP, Harrigan SM, et al. Outcome in early-onset schizophrenia revisited: findings from the Early Psychosis Prevention and Intervention Centre long-term follow-up study. Schizophr Res 2011;131:112-19
   PubMed Web of Science ®Google Scholar
• Schimmelmann BG, Conus P, Cotton S, et al. Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients. Schizophr Res 2007;95:1-8
   PubMed Web of Science ®Google Scholar
• Schimmelmann BG, Huber CG, Lambert M, et al. Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J Psychiatr Res 2008;42:982-90
   PubMed Web of Science ®Google Scholar
• Ballageer T, Malla A, Manchanda R, et al. Is adolescent-onset first-episode psychosis different from adult onset? J Am Acad Child Adolesc Psychiatry 2005;44:782-9
   PubMed Web of Science ®Google Scholar
• Tang JY, Chang WC, Hui CL, et al. Prospective relationship between duration of untreated psychosis and 13-year clinical outcome: a first-episode psychosis study. Schizophr Res 2014;153:1-8
   PubMed Web of Science ®Google Scholar
• Findling RL, Robb A, Nyilas M, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008;165:1432-41
   PubMed Web of Science ®Google Scholar
• Kryzhanovskaya L, Schulz SC, McDougle C, et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009;48:60-70
   PubMed Web of Science ®Google Scholar
• Haas M, DelBello MP, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2009;11:687-700
   PubMed Web of Science ®Google Scholar
• Haas M, Unis AS, Armenteros J, et al. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 2009;19:611-21
   PubMed Web of Science ®Google Scholar
• Singh J, Robb A, Vijapurkar U, et al. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry 2011;70:1179-87
   PubMed Web of Science ®Google Scholar
• Findling RL, McKenna K, Earley WR, et al. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol 2012;22:327-42
   PubMed Web of Science ®Google Scholar
• Findling RL, Cavus I, Pappadopulos E, et al. Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study. J Child Adolesc Psychopharmacol 2013;23:531-44
   PubMed Web of Science ®Google Scholar
• Correll CU. Safety and tolerability of antipsychotic treatment in young patients with schizophrenia. J Clin Psychiatry 2011;72:e26
   PubMedGoogle Scholar
• Schimmelmann BG, Schmidt SJ, Carbon M, Correll CU. Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. Curr Opin Psychiatry 2013;26:219-30
   PubMed Web of Science ®Google Scholar
• Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 2006;63:721-30
   PubMed Web of Science ®Google Scholar
• Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry 2008;63:524-9
   PubMed Web of Science ®Google Scholar
• Gogtay N, Rapoport J. Clozapine use in children and adolescents. Expert Opin Pharmacother 2008;9:459-65
   PubMed Web of Science ®Google Scholar
• Masi G, Liboni F. Management of schizophrenia in children and adolescents: focus on pharmacotherapy. Drugs 2011;71:179-208
   PubMed Web of Science ®Google Scholar
• Kumar A, Datta SS, Wright SD, et al. Atypical antipsychotics for psychosis in adolescents. Cochrane Database Syst Rev 2013;10:CD009582
   Google Scholar
• Datta SS, Kumar A, Wright SD, et al. Evidence base for using atypical antipsychotics for psychosis in adolescents. Schizophr Bull 2014;40:252-4
   PubMed Web of Science ®Google Scholar
• De Hert M, Dobbelaere M, Sheridan EM, et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 2011;26:144-58
   PubMed Web of Science ®Google Scholar
• De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011;8:114-26
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-62
   PubMed Web of Science ®Google Scholar
• Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008;165:1420-31
   PubMed Web of Science ®Google Scholar
• Findling RL, Johnson JL, McClellan J, et al. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry 2010;49:583-94
   PubMed Web of Science ®Google Scholar
• Olfson M, Gerhard T, Huang C, et al. Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia. Schizophr Bull 2012;38:845-53
   PubMed Web of Science ®Google Scholar
• Guideline on clinical investigation of medicinal products, including depot preparations in the treatment of schizophrenia, EMA/CHMP/40072/2010 Rev.1. European Medicines Agency: Committee for Medicinal Products for Human Use. 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/10/WC500133437.pdf [Last accessed 1 March 2014]
   Google Scholar
• Angermeyer MC, Matschinger H, Schomerus G. Attitudes towards psychiatric treatment and people with mental illness: changes over two decades. Br J Psychiatry 2013;203:146-51
   PubMed Web of Science ®Google Scholar
• Linscott RJ, Cross FV. The burden of awareness of psychometric risk for schizophrenia. Psychiatry Res 2009;166:184-91
   PubMed Web of Science ®Google Scholar
• Maruta T, Volpe U, Gaebel W, et al. Should schizophrenia still be named so? Schizophr Res 2014;152:305-6
   PubMed Web of Science ®Google Scholar
• Sartorius N, Chiu H, Heok KE, et al. Name change for schizophrenia. Schizophr Bull 2014;40:255-8
   PubMed Web of Science ®Google Scholar
• Cannon M, Caspi A, Moffitt TE, et al. Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. Arch Gen Psychiatry 2002;59:449-56
   PubMed Web of Science ®Google Scholar
• Mattai A, Chavez A, Greenstein D, et al. Effects of clozapine and olanzapine on cortical thickness in childhood-onset schizophrenia. Schizophr Res 2010;116:44-8
   PubMed Web of Science ®Google Scholar
• Asarnow RF, Forsyth JK. Genetics of childhood-onset schizophrenia. Child Adolesc Psychiatr Clin N Am 2013;22:675-87
   PubMed Web of Science ®Google Scholar
• Addington AM, Rapoport JL. The genetics of childhood-onset schizophrenia: when madness strikes the prepubescent. Curr Psychiatry Rep 2009;11:156-61
   PubMed Web of Science ®Google Scholar
• Rapoport JL, Gogtay N. Childhood onset schizophrenia: support for a progressive neurodevelopmental disorder. Int J Dev Neurosci 2011;29:251-8
   PubMed Web of Science ®Google Scholar
• Ahn K, Gotay N, Andersen TM, et al. High rate of disease-related copy number variations in childhood onset schizophrenia. Mol Psychiatry 2014;19:568-72
   PubMed Web of Science ®Google Scholar
• Addington AM, Gornick M, Sporn AL, et al. Polymorphisms in the 13q33.2 gene G72/G30 are associated with childhood-onset schizophrenia and psychosis not otherwise specified. Biol Psychiatry 2004;55:976-80
   PubMed Web of Science ®Google Scholar
• Gornick MC, Addington AM, Sporn A, et al. Dysbindin (DTNBP1, 6p22.3) is associated with childhood-onset psychosis and endophenotypes measured by the Premorbid Adjustment Scale (PAS). J Autism Dev Disord 2005;35:831-8
   PubMed Web of Science ®Google Scholar
• Addington AM, Gornick M, Duckworth J, et al. GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical gray matter volume loss. Mol Psychiatry 2005;10:581-8
   PubMed Web of Science ®Google Scholar
• Addington AM, Gornick MC, Shaw P, et al. Neuregulin 1 (8p12) and childhood-onset schizophrenia: susceptibility haplotypes for diagnosis and brain developmental trajectories. Mol Psychiatry 2007;12:195-205
   PubMed Web of Science ®Google Scholar
• Sporn A, Addington A, Reiss AL, et al. 22q11 deletion syndrome in childhood onset schizophrenia: an update. Mol Psychiatry 2004;9:225-6
   PubMed Web of Science ®Google Scholar
• McCarthy SE, Makarov V, Kirov G, et al. Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet 2009;41:1223-7
   PubMed Web of Science ®Google Scholar
• Lee Y, Mattai A, Long R, et al. Microduplications disrupting the MYT1L gene (2p25.3) are associated with schizophrenia. Psychiatr Genet 2012;22:206-9
   PubMed Web of Science ®Google Scholar
• Wilson NK, Lee Y, Long R, et al. A Novel Microduplication in the neurodevelopmental gene SRGAP3 that segregates with psychotic illness in the family of a COS proband. Case Rep Genet 2011;2011:585893
   Google Scholar
• Gauthier J, Siddiqui TJ, Huashan P, et al. Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia. Hum Genet 2011;130:563-73
   PubMed Web of Science ®Google Scholar
• Rees E, Walters JT, Georgieva L, et al. Analysis of copy number variations at 15 schizophrenia-associated loci. Br J Psychiatry 2014;204:108-14
   PubMed Web of Science ®Google Scholar
• Rujescu D, Ingason A, Cichon S, et al. Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet 2009;18:988-96
   PubMed Web of Science ®Google Scholar
• Greenstein D, Lerch J, Shaw P, et al. Childhood onset schizophrenia: cortical brain abnormalities as young adults. J Child Psychol Psychiatry 2006;47:1003-12
   PubMed Web of Science ®Google Scholar
• Refusal of the marketing authorisation for Fanaptum (iloperidone), EMA/793402/2012, EMEA/H/C/002371. European Medicines Agency. 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002371/WC500136253.pdf [Last accessed 1 March 2014]
   Google Scholar
• Poyurovsky M, Fuchs C, Pashinian A, et al. Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology (Berl) 2013;226:615-22
   PubMed Web of Science ®Google Scholar
• Larr AS, Vakhrusheva J, Marino P, Maavan L. A double-blind, placebo controlled trial of betahistine to ameliorate antipsychotic associated weight gain in adolescents and young adults: Preliminary safety and efficacy data. Schizophrenia Res 2012;136:S355
   Google Scholar
• Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 2010;35:1520-30
   PubMed Web of Science ®Google Scholar
• Reeves GM, Keeton C, Correll CU, et al. Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods. Child Adolesc Psychiatry Ment Health 2013;7:31
   PubMedGoogle Scholar
• Nwosu B, Meltzer B. Short term effects of vitamin D supplementation on body mass index in overweight adolescents receiving second generation antipsychotics. Schizophrenia Res 2010;31:265
   Google Scholar
• Macdonald K, Macdonald TM. The peptide that binds: a systematic review of oxytocin and its prosocial effects in humans. Harv Rev Psychiatry 2010;18:1-21
   PubMed Web of Science ®Google Scholar
• De Berardis D, Marini S, Iasevoli F, et al. The role of intranasal oxytocin in the treatment of patients with schizophrenia: a systematic review. CNS Neurol Disord Drug Targets 2013;12:252-64
   PubMed Web of Science ®Google Scholar
• Macdonald K, Feifel D. Oxytocin in schizophrenia: a review of evidence for its therapeutic effects. Acta Neuropsychiatr 2012;24:130-46
   PubMed Web of Science ®Google Scholar
• Rosenfeld AJ, Lieberman JA, Jarskog LF. Oxytocin, Dopamine, and the Amygdala: a Neurofunctional Model of Social Cognitive Deficits in Schizophrenia. Schizophr Bull 2011;37:1077-87
   PubMed Web of Science ®Google Scholar
• Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia – a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008;64:361-8
   PubMed Web of Science ®Google Scholar
• Lavoie S, Murray MM, Deppen P, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008;33:2187-99
   PubMed Web of Science ®Google Scholar
• Carmeli C, Knyazeva MG, Cuenod M, Do KQ. Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial. PLoS One 2012;7:e29341
   PubMed Web of Science ®Google Scholar
• Berk M, Malhi GS, Gray LJ, Dean OM. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci 2013;34:167-77
   PubMed Web of Science ®Google Scholar
• Noetzel MJ, Jones CK, Conn PJ. Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling. Discov Med 2012;14:335-43
   PubMed Web of Science ®Google Scholar
• Kau KS, Madayag A, Mantsch JR, et al. Blunted cystine-glutamate antiporter function in the nucleus accumbens promotes cocaine-induced drug seeking. Neuroscience 2008;155:530-7
   PubMed Web of Science ®Google Scholar
• Moran MM, McFarland K, Melendez RI, et al. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci 2005;25:6389-93
   PubMed Web of Science ®Google Scholar
• Bayer TA, Falkai P, Maier W. Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the two hit hypothesis. J Psychiatr Res 2011;33:543-8
   Web of Science ®Google Scholar
• Woods SW, Addington J, Cadenhead KS, et al. Validity of the prodromal risk syndrome for first psychosis: findings from the north american prodrome longitudinal study. Schizophr Bull 2009;35:894-908
   PubMed Web of Science ®Google Scholar
• Peet M. Omega-3 polyunsaturated fatty acids in the treatment of schizophrenia. Isr J Psychiatry Relat Sci 2008;45:19-25
   PubMed Web of Science ®Google Scholar
• Amminger GP, Schafer MR, Papageorgiou K, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010;67:146-54
   PubMed Web of Science ®Google Scholar
• Amminger GP, McGorry PD. Update on omega-3 polyunsaturated fatty acids in early-stage psychotic disorders. Neuropsychopharmacology 2012;37:309-10
   PubMed Web of Science ®Google Scholar
• Crupi R, Marino A, Cuzzocrea S. n-3 fatty acids: role in neurogenesis and neuroplasticity. Curr Med Chem 2013;20:2953-63
   PubMed Web of Science ®Google Scholar
• Bondi CO, Taha AY, Tock JL, et al. Adolescent behavior and dopamine availability are uniquely sensitive to dietary omega-3 fatty acid deficiency. Biol Psychiatry 2014;75:38-46
   PubMed Web of Science ®Google Scholar
• Kantrowitz J, Javitt D. Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Clin Schizophr Relat Psychoses 2010;4:189-200
   PubMedGoogle Scholar
• Buchanan RW, Javitt DC, Marder SR, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007;164:1593-602
   PubMed Web of Science ®Google Scholar
• Kantrowitz JT, Epstein M. Modulation of N-methyl-D-aspartate (NMDAR)-type glutamate receptors in psychiatric disorders. Neuropsychopharmacology 2013;38:S273
   Google Scholar
• Cornblatt BA, Lencz T, Smith CW, et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry 2007;68:546-57
   PubMed Web of Science ®Google Scholar
• Pinna G, Costa E, Guidotti A. SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake. Curr Opin Pharmacol 2009;9:24-30
   PubMed Web of Science ®Google Scholar
• Marx CE, Bradford DW, Hamer RM, et al. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. Neuroscience 2011;191:78-90
   PubMed Web of Science ®Google Scholar
• Roche provides update on the first two of six phase III studies of bitopertin in schizophrenia. Roche. 2014. Available from: http://www.roche.com/media/media_releases/med-cor-2014-01-21.htm [Last accessed 1 3 2014]
   Google Scholar
• Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012;37:4-15
   PubMed Web of Science ®Google Scholar
• Lilly stops Phase III development of pomaglumetad methionil for the treatment of schizophrenia based on efficacy results. Eli Lilly. and Co. 2012. Available from: https://investor.lilly.com/releasedetail.cfm?ReleaseID=703018 [Last accessed 12 March 2014]
   Google Scholar
• Thompson PM, Vidal C, Giedd JN, et al. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci USA 2001;98:11650-5
   PubMed Web of Science ®Google Scholar
• Vidal CN, Rapoport JL, Hayashi KM, et al. Dynamically spreading frontal and cingulate deficits mapped in adolescents with schizophrenia. Arch Gen Psychiatry 2006;63:25-34
   PubMed Web of Science ®Google Scholar
• Green SM, Denmark TK, Cline J, et al. Ketamine sedation for pediatric critical care procedures. Pediatr Emerg Care 2001;17:244-8
   PubMed Web of Science ®Google Scholar
• Kinon BJ. The development of pomaglumetad methionil as an innovative glutamate-based pharmacotherapy for schizophrenia. Paper presented at 52nd ACNP Meeting; 10 December 2013; Hollywood, FL
   Google Scholar